

Synthesis and antimicrobial potential of Mannich bases of 4-chloro-3-{4-(chlorobenzoyloxy)-benzoylhydrazono}-indolin-2-ones

Nisheeth Rastogi^{a*}, Darwin Anil Harrison^a, Diwakar Tripathi^b and Sarveshwar Shukla^b

^aDepartment of Chemistry, Lucknow Christian Post-Graduate College, Lucknow-226 018, Uttar Pradesh, India

E-mail : nisheethrastogi2003@yahoo.co.in

^bDepartment of Chemistry, Sri Jai Narain Post-Graduate College, Lucknow-226 001, Uttar Pradesh, India

Manuscript received 3 March 2009, accepted 26 May 2009

Abstract : 4-Chloro-3-{4-(chlorobenzoyloxy)-benzoylhydrazono}-indolin-2-ones (1-4) were synthesised by the condensation of 4-(chlorobenzoyloxy)-benzoylhydrazines and 4-chloroisatin. On being subjected to aminomethylation in the presence of formaldehyde and heterocyclic secondary amines, indolinones 1-4, furnished aminomethylated indolinones (Mannich bases) 5-20. The structures of the compounds have been established by means of elemental analysis and spectral data (IR, PMR and Mass). The compounds have been screened for their antimicrobial potential against human pathogenic bacteria and fungi.

Keywords : Isatin, aminomethylation, Mannich bases, antimicrobial agents.

Introduction

Isatins¹ and their derivatives have been reported to possess broad spectrum of biological activities viz. antiviral², cytotoxic³, antimicrobial⁴, antifertility⁵, amoebicidal⁶, anti-HIV⁷, antileukemic⁸, anticonvulsant⁹, CNS-depressant¹⁰, analgesic and antiinflammatory¹¹. Recently a review¹² has been published on biological potential of isatin derivatives. In the light of these observations and in continuation¹³ of our work on biologically active heterocycles, synthesis of a new series of Schiff's bases [4-chloro-3-{4-(chlorobenzoyloxy)-benzoylhydrazono}-indolin-2-ones] (1-4) and Mannich bases [1-aminomethyl-4-chloro-3-{4-(chlorobenzoyloxy)-benzoylhydrazono}-indolin-2-ones] (5-20) is being reported in the present communication.

Results and discussion


Methylparaben was treated with chlorosubstituted benzyl chlorides to get methyl-4-(chlorobenzoyloxy)-benzoates which on hydrazinolysis gave 4-(chlorobenzoyloxy)-benzoylhydrazines. Acid catalysed condensation of hy-

drazines with 4-chloroisatin in equimolar proportion gave 4-chloro-3-{4-(chlorobenzoyloxy)-benzoylhydrazono}-indolin-2-ones (1-4). On being subjected to aminomethylation¹⁴ with heterocyclic secondary amines in the presence of formaldehyde (1-4), gave 1-aminomethyl-4-chloro-3-{4-(chlorobenzoyloxy)-benzoylhydrazono}-indolin-2-ones (5-20) (Scheme 1).

Antimicrobial activity :

Compounds 5-20 were tested for their antimicrobial potential against human pathogenic bacteria viz. *Escherichia coli* (ATCC 9637) (EC), *Pseudomonas aeruginosa* (ATCC- BAA427) (PA), *Staphylococcus aureus* (ATCC 25923) (SA), *Klebsiella pneumoniae* (ATCC 27736) (KP) and fungi viz. *Candida albicans* (CA), *Cryptococcus neoformans* (CN), *Sporothrix schenckii* (SS), *Trichophyton mentagrophytes* (TM), *Aspergillus fumigatus* (AF) and *Candida parapsilosis* (ATCC 22019) (CP) by tube dilution technique¹⁵ recommended by NCCLS. Compounds were tested at maximum concentration 50 µg/mL and MIC value in µg/mL were determined and results are presented in Table 2. Gentamycin and fluconazole were taken as standard for bacteria and fungi respectively.

*Address for correspondence : 231/103, Ka, Bagh Macca, Khinni Tare, Raja Bazar, Lucknow-226 003, Uttar Pradesh, India





(i) Chlorobenzyl chlorides, K_2CO_3
(anhyd.)

(ii) $\text{N}_2\text{H}_4 \cdot \text{H}_2\text{O}$

(iii) 4-Chloroisatin, EtOH, AcOH

(iv) Amines, CH_2O , DMF

$\text{R}_1, \text{R}_2, \text{R}_3 = \text{H, Cl}$,



Scheme 1

Experimental

The melting points were taken in open capillaries in sulfuric acid bath and are uncorrected. IR spectra were recorded in KBr on a Perkin-Elmer RX1 spectrophotometer and PMR on Bruker Avance 400 spectrometer. CDCl_3 was used as solvent and TMS as internal refer-

ence. Chemical shifts are expressed in δ ppm. Mass spectra were recorded on Jeol-JMS-D-300 spectrometer at 70 eV with direct inlet system. Elemental analysis data were obtained on Carlo Erba 1108 analyser. Purity of the compounds was checked by TLC silica gel G plates and spots were located by exposure to iodine vapors. The physical data of the compounds prepared, are presented in Table 1.

Note

Table 1. Characterization data of the compounds prepared

| Compd. | R ₁ | R ₂ | R ₃ | R ₄ | M.p. (°C) | Yield (%) | Molecular formula | Elemental analysis (%): | | |
|--------|----------------|----------------|----------------|-----------------|--------------|--------------|---|-------------------------|-------------|---------------|
| | | | | | | | | Found (Calcd.) | | |
| | | | | | | | | C | H | N |
| 1 | H | H | H | - | 260-262 | 72 | C ₂₂ H ₁₆ ClN ₃ O ₃ | - | - | - |
| 2 | Cl | H | H | - | 264-266 | 72 | C ₂₂ H ₁₆ Cl ₂ N ₃ O ₃ | - | - | - |
| 3 | H | Cl | H | - | 254-256 | 70 | C ₂₂ H ₁₆ Cl ₂ N ₃ O ₃ | - | - | - |
| 4 | H | H | Cl | - | 258-260 | 76 | C ₂₂ H ₁₆ Cl ₂ N ₃ O ₃ | - | - | - |
| 5 | H | H | H | Morpholino | 172-174 | 86 | C ₂₇ H ₂₅ ClN ₄ O ₄ | 59.88 (60.00) | 4.58 (4.62) | 10.28 (10.37) |
| 6 | H | H | H | Piperidino | 198-200 | 75 | C ₂₈ H ₂₇ ClN ₄ O ₃ | 65.39 (62.45) | 4.88 (5.01) | 10.34 (10.40) |
| 7 | H | H | H | N-Me-Piperazino | 180-182 | 72 | C ₂₈ H ₂₈ ClN ₅ O ₃ | 60.66 (60.75) | 4.98 (5.06) | 12.60 (12.65) |
| 8 | H | H | H | Pyrrolidino | 174-176 | 86 | C ₂₇ H ₂₅ ClN ₄ O ₃ | 61.74 (61.83) | 4.66 (4.77) | 12.60 (10.68) |
| 9 | Cl | H | H | Morpholino | 174-176 | 80 | C ₂₇ H ₂₄ Cl ₂ N ₄ O ₄ | 59.80 (60.00) | 4.55 (4.62) | 10.31 (10.37) |
| 10 | Cl | H | H | Piperidino | 166-168 | 73 | C ₂₈ H ₂₆ Cl ₂ N ₄ O ₃ | 62.35 (62.45) | 4.90 (5.01) | 10.32 (10.40) |
| 11 | Cl | H | H | N-Me-Piperazino | 162-164 | 68 | C ₂₈ H ₂₇ Cl ₂ N ₅ O ₃ | 60.62 (60.75) | 5.00 (5.06) | 12.59 (12.65) |
| 12 | Cl | H | H | Pyrrolidino | 172-174 | 77 | C ₂₇ H ₂₄ Cl ₂ N ₄ O ₃ | 61.78 (61.83) | 4.68 (4.77) | 10.50 (10.60) |
| 13 | H | Cl | H | Morpholino | 186-188 | 80 | C ₂₇ H ₂₄ Cl ₂ N ₄ O ₄ | 59.82 (60.00) | 4.58 (4.62) | 10.29 (10.37) |
| 14 | H | Cl | H | Piperidino | 180-182 | 70 | C ₂₈ H ₂₆ Cl ₂ N ₄ O ₃ | 62.40 (62.45) | 4.90 (5.01) | 10.31 (10.40) |
| 15 | H | Cl | H | N-Me-Piperazino | 158-160 | 70 | C ₂₈ H ₂₇ Cl ₂ N ₅ O ₃ | 60.66 (60.75) | 4.90 (5.06) | 12.55 (12.65) |
| 16 | H | Cl | H | Pyrrolidino | 156-158 | 77 | C ₂₇ H ₂₄ Cl ₂ N ₄ O ₃ | 61.79 (61.83) | 4.00 (4.77) | 10.60 (10.68) |
| 17 | H | H | Cl | Morpholino | 196-198 | 82 | C ₂₇ H ₂₄ Cl ₂ N ₄ O ₄ | 59.92 (60.00) | 4.57 (4.62) | 10.33 (10.37) |
| 18 | H | H | Cl | Piperidino | 190-192 | 68 | C ₂₈ H ₂₆ Cl ₂ N ₄ O ₃ | 62.32 (62.45) | 4.90 (5.01) | 10.33 (10.40) |
| 19 | H | H | Cl | N-Me-Piperazino | 174-176 | 68 | C ₂₈ H ₂₇ Cl ₂ N ₅ O ₃ | 62.66 (60.75) | 4.88 (5.06) | 12.57 (12.65) |
| 20 | H | H | Cl | Piperidino | 172-174 | 72 | C ₂₇ H ₂₄ Cl ₂ N ₄ O ₃ | 61.70 (61.83) | 4.69 (4.77) | 10.60 (10.68) |

Table 2. Minimum Inhibitory Concentration MIC (µg/mL) of compounds against pathogenic bacteria and fungi by tube dilution technique

| Compd. | EC | PA | SA | KP | CA | CN | SS | TM | AF | CP |
|-------------|------|-----|------|------|------|------|------|------|-----|------|
| 5 | >50 | >50 | >50 | >50 | 50 | >50 | >50 | 6.25 | >50 | >50 |
| 6 | >50 | >50 | >50 | >50 | >50 | >50 | >50 | 6.25 | >50 | >50 |
| 7 | >50 | >50 | 12.5 | >50 | >50 | >50 | >50 | 12.5 | >50 | >50 |
| 8 | >50 | >50 | >50 | 50 | >50 | >50 | >50 | 25 | >50 | >50 |
| 9 | >50 | 50 | >50 | 50 | >50 | 50 | 3.12 | >50 | >50 | >50 |
| 10 | >50 | 50 | 12.5 | 50 | >50 | 25 | >50 | >50 | >50 | 6.25 |
| 11 | >50 | >50 | 12.5 | 25 | 50 | >50 | >50 | >50 | >50 | 3.12 |
| 12 | >50 | >50 | >50 | 25 | 25 | >50 | >50 | >50 | >50 | 50 |
| 13 | >50 | 25 | >50 | 25 | >50 | >50 | 3.12 | >50 | >50 | 50 |
| 14 | >50 | >50 | >50 | >50 | >50 | >50 | 50 | 3.12 | >50 | >50 |
| 15 | >50 | >50 | >50 | >50 | 12.5 | 3.12 | 50 | >50 | >50 | >50 |
| 16 | >50 | >50 | >50 | >50 | 12.5 | 3.12 | >50 | 25 | >50 | >50 |
| 17 | >50 | >50 | >50 | >50 | 50 | 25 | >50 | >50 | >50 | >50 |
| 18 | >50 | >50 | >50 | >50 | >50 | 25 | >50 | >50 | >50 | >50 |
| 19 | >50 | >50 | >50 | >50 | >50 | 50 | >50 | >50 | >50 | >50 |
| 20 | >50 | >50 | >50 | >50 | >50 | 25 | >50 | >50 | >50 | >50 |
| Gentamycin | 0.18 | 25 | 6.25 | 0.18 | - | - | - | - | - | - |
| Fluconazole | - | - | - | - | 0.50 | 1.0 | 2.0 | 1.0 | 2.0 | 1.0 |

4-Chloro-3-{4-(chlorobenzyloxy)-benzoylhydrazono}-indolin-2-ones (1-4) : (General method) :

A mixture of 4-(chlorobenzyloxy)-benzoylhydrazines (0.01 mol) and 4-chloroisatin (0.01 mol) in ethanol (50 mL) containing 3–4 drops of glacial acetic acid was refluxed for one hour and left overnight at room temperature. The solid product so obtained was washed with methanol; **1** IR (cm^{-1}) : 3417.5, 3161.3 (NH), 1743.6, 1670.6 (-CO-), 1250.4 (-CH₂O-), 744.1 (C-Cl); MS (m/z) : 405 (M⁺), 407 (M+2); **2** IR (cm^{-1}) : 3482.0, 3151.8 (NH), 1700.6, 1667.3 (-CO-), 1252.0 (-CH₂O-), 751.9 (C-Cl); MS (m/z) : 440 (M⁺), 442 (M+2), 444 (M+4); **3** IR (cm^{-1}) : 3460.9, 3166.4 (NH), 1743.4, 1673.1 (-CO-), 1251.3 (-CH₂O-), 778.2 (C-Cl); **4** IR (cm^{-1}) : 3454.9, 3149.9 (NH), 1704.2, 1671.7 (-CO-), 1248.4 (-CH₂O-), 780.1 (C-Cl).

1-Aminomethyl-4-chloro-3-{4-(chlorobenzyloxy)-benzoylhydrazono}-indolin-2-ones (5-20) : (General method) :

To a suspension of **1-4** (0.005 mol) in DMF, formaldehyde (0.5 mL, 37%) and amines (0.005 mol) were added with vigorous stirring. The solution was warmed for 2 min on a water bath and left overnight at room temperature. The solid product thus obtained was filtered, dried and recrystallized from chloroform : pet ether (60–80 °C) (1 : 1); **5** IR (cm^{-1}) : 3450.0 (NH), 2929.9 (>N-CH₂-N<), 1684.3, 1658.4 (-CO-), 1249.2 (-CH₂O-), 1146.5 (-C-O-C-), 758.7 (C-Cl); PMR δ (ppm) : 2.61–2.64 (4H, t, -CH₂-N-CH₂-), 3.70–3.72 (4H, t, -CH₂-O-CH₂-), 4.50 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 6.97–8.04 (12H, m, Ar-H), 13.86 (1H, s, CONH); MS (m/z) : 504 (M⁺), 506 (M+2); **6** IR (cm^{-1}) : 3440.4 (NH), 2932.6 (>N-CH₂-N<), 1686.8, 1654.6 (-CO-), 1248.0 (-CH₂O-), 758.2 (C-Cl); PMR δ (ppm) : 1.42–1.59 (6H, m, -CH₂CH₂CH₂-), 2.52–2.58 (4H, t, -CH₂-N-CH₂-), 4.50 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 7.00–8.04 (12H, m, Ar-H), 13.99 (1H, s, CONH); MS (m/z) : 502 (M⁺), 504 (M+2); **7** PMR δ (ppm) : 1.99 (3H, s, N-Me), 2.28–2.41 (4H, t, -CH₂-N-CH₂-), 2.52–2.62 (4H, t, -CH₂-N(Me)-CH₂-), 4.50 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 6.98–8.04 (12H, m, Ar-H), 13.89 (1H, s, CONH); MS (m/z) : 517 (M⁺), 519 (M+2); **8** IR (cm^{-1}) : 3421.7 (NH), 2965.6 (>N-CH₂-N<), 1683.2, 1654.6 (-CO-), 1248.8 (-CH₂O-),

761.9 (C-Cl); PMR δ (ppm) : 1.24–1.57 (4H, m, -CH₂CH₂-), 2.27–2.67 (4H, t, -CH₂-N-CH₂-), 4.68 (2H, s, >N-CH₂-N<), 5.15 (2H, s, -CH₂O-), 7.00–8.04 (12H, m, Ar-H), 13.92 (1H, s, CONH); MS (m/z) : 488 (M⁺), 490 (M+2); **9** IR (cm^{-1}) : 3434.3 (NH), 2927.0 (>N-CH₂-N<), 1681.1, 1650.2 (-CO-), 1247.5 (-CH₂O-), 1171.8 (-C-O-C-), 753.9 (C-Cl); PMR δ (ppm) : 2.61–2.64 (4H, t, -CH₂-N-CH₂-), 3.68–3.71 (4H, t, -CH₂-O-CH₂-), 4.50 (2H, s, >N-CH₂-N<), 5.26 (2H, s, -CH₂O-), 6.97–8.05 (11H, m, Ar-H), 14.04 (1H, s, CONH); **10** IR (cm^{-1}) : 3436.8 (NH), 2929.6 (>N-CH₂-N<), 1685.3, 1649.2 (-CO-), 1250.2 (-CH₂O-), 753.1 (C-Cl); PMR δ (ppm) : 1.44–1.59 (6H, m, -CH₂CH₂CH₂-), 2.55–2.58 (4H, t, -CH₂-N-CH₂-), 4.66 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 7.00–8.05 (11H, m, Ar-H), 14.01 (1H, s, CONH); MS (m/z) : 538 (M⁺), 540 (M+2); **12** IR (cm^{-1}) : 3446.3 (NH), 2933.9 (>N-CH₂-N<), 1681.6, 1652.3 (-CO-), 1252.2 (-CH₂O-), 753.1 (C-Cl); PMR δ (ppm) : 1.25–1.36 (4H, m, -CH₂CH₂-), 2.69–2.72 (4H, t, -CH₂-N-CH₂-), 4.68 (2H, s, >N-CH₂-N<), 5.25 (2H, s, -CH₂O-), 7.03–8.05 (11H, m, Ar-H), 14.04 (1H, s, CONH); **14** IR (cm^{-1}) : 3421.2 (NH), 2941.8 (>N-CH₂-N<), 1686.4, 1651.8 (-CO-), 1252.0 (-CH₂O-), 777.4 (C-Cl); PMR δ (ppm) : 1.62–1.81 (6H, m, -CH₂CH₂CH₂-), 2.50–2.71 (4H, t, -CH₂-N-CH₂-), 4.52 (2H, s, >N-CH₂-N<), 5.35 (2H, s, -CH₂O-), 6.97–8.04 (11H, m, Ar-H), 13.92 (1H, s, CONH); **15** IR (cm^{-1}) : 3447.7 (NH), 2938.3 (>N-CH₂-N<), 1695.3, 1661.2 (-CO-), 1251.2 (-CH₂O-), 773.0 (C-Cl); PMR δ (ppm) : 1.89 (3H, s, N-Me), 2.27–2.43 (4H, t, -CH₂-N-CH₂-), 2.49–2.67 (4H, t, -CH₂-N(Me)CH₂-), 4.52 (2H, s, >N-CH₂-N<), 5.35 (2H, s, -CH₂O-), 7.00–8.04 (11H, m, Ar-H), 13.98 (1H, s, CONH); MS (m/z) : 553 (M⁺), 555 (M+2); **17** IR (cm^{-1}) : 3458.9 (NH), 2950.4 (>N-CH₂-N<), 1698.2, 1672.8 (-CO-), 1248.3 (-CH₂O-), 1153.6 (-C-O-C-), 775.5 (C-Cl); PMR δ (ppm) : 2.58–2.61 (4H, t, -CH₂-N-CH₂-), 3.69–3.72 (4H, t, -CH₂-O-CH₂-), 4.68 (2H, s, >N-CH₂-N<), 5.20 (2H, s, -CH₂O-), 7.00–8.04 (11H, m, Ar-H), 13.84 (1H, s, CONH); **20** IR (cm^{-1}) : 3448.1 (NH), 2925.0 (>N-CH₂-N<), 1700.1, 1676.9 (-CO-), 1250.1 (-CH₂O-), 764.4 (C-Cl); PMR δ (ppm) : 1.25–1.42 (4H, m, -CH₂CH₂-), 2.36–2.49 (4H, t, -CH₂-N-CH₂-), 4.68 (2H, s, >N-CH₂-N<), 5.20 (2H, s, -CH₂O-), 7.01–8.05 (11H, m, Ar-H), 13.97 (1H, s, CONH).

Acknowledgement

The authors are thankful to the Principal, Sri J.N.P.G. College for providing laboratory facilities.

References

1. F. D. Popp, *Adv. Heterocyclic Chem.*, 1975, **18**, 1.
2. P. Selvam, N. Murgesh, M. Chandramohan, E. De Clercq, E. Keyaerts, L. Vijgen, P. Maes, J. Neyts and M. V. Ransti, *Indian J. Pharm. Sci.*, 2008, **70**, 91.
3. M. M. Haque and M. R. Islam, *Bangladesh J. Pharmaco.*, 2008, **3**, 21; M. M. Hossain, N. Islam, R. Khan and M. R. Islam, *Bangladesh J. Pharmaco.*, 2007, **2**, 66; A. Gursay and N. Karali, *Eur. J. Med. Chem.*, 2003, **38**, 633; L. Matesic, J. M. Locke, J. B. Bremner, S. G. Pyne, D. Skropeta, M. Ranson and K. L. Vine, *Bioorg. Med. Chem.*, 2008, **16**, 3118.
4. M. Kupinic, M. Medic-Skaric, M. Movrin and D. Maysinger, *J. Pharm. Sci.*, 2006, **64**, 459; A. Patel, S. Bari, G. Talele, J. Patel and M. Sarangapani, *Iranian J. Pharm. Res.*, 2006, **4**, 249; S. George, M. K. Parameswaran, A. J. Chakraborty and T. K. Ravi, *Acta Pharm.*, 2008, **58**, 119.
5. K. C. Joshi, R. Jain, P. Chand and S. Garg, *J. Indian Chem. Soc.*, 1983, **60**, 760.
6. R. S. Varma and P. K. Garg, *Indian J. Pharm. Sci.*, 1980, **43**, 8.
7. S. N. Pandeya, D. Sriram, E. De Clercq, C. Pannecouque and M. Witrouw, *Indian J. Pharm. Sci.*, 1998, **60**, 207.
8. M. Rajapadhye and F. E. Popp, *J. Heterocyclic Chem.*, 1984, **21**, 289.
9. M. Imran, O. Alam, D. Kaushik and S. A. Khan, *Indian J. Heterocyclic Chem.*, 2007, **16**, 251.
10. R. S. Varma, R. Prakash and C. R. Prasad, *J. Chem. Soc. Pak.*, 1986, **8**, 17; R. S. Varma and S. Chauhan, *Indian J. Chem., Sect. B*, 1988, **27**, 438; R. S. Varma, R. K. Pandey and P. Kumar, *Indian J. Pharm. Sci.*, 1982, **44**, 132.
11. V. A. Muthukumar, S. George and V. Vaidhyalingam, *Bio. Pharm. Bull.*, 2008, **31**, 1461.
12. S. N. Pandeya, S. Smitha, M. Jyoti and S. K. Sridhar, *Acta Pharm.*, 2005, **55**, 27.
13. N. Rastogi, R. Sethi, R. S. Varma and D. Tripathi, *J. Indian Chem. Soc.*, 2008, **85**, 513; N. Rastogi, P. Kant, D. A. Harrison, R. Sethi and D. Tripathi, *Indian J. Heterocyclic Chem.*, 2009, **18** (in Press).
14. R. S. Varma, *J. Indian Chem. Soc.*, 2004, **81**, 627.
15. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution in antimicrobial susceptibility tests : Approved standard M2-A5. Villanova, P.A.; NCCLS, 1993.